TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment C
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment C
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
Study: NCT01512537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and calcium
Description: 1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
Study: NCT00059761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02722239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (Forxiga)
Description: co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment C
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment D
Description: The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
Study: NCT04786496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITP+SA Wise intervention
Description: Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITP Wise intervention
Description: Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control condition
Description: The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
Study: NCT03560843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction
Study: NCT03751748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFR implantation
Description: Implantation of atrial flow regulator (AFR) device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
Study: NCT02970123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less, Interact, Move More (SLIMM)
Study: NCT04411680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care for COVID-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care for COVID-19
Study: NCT03129841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early dinner+Diet
Description: Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late dinner+Diet
Description: Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
Study: NCT02173886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR and XL
Study: NCT01341938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commit® nicotine lozenges (4 mg) & self-help materials
Description: Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commit® nicotine lozenges (4 mg) & self-help materials
Description: Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials
Description: Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials
Description: Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling & self-help materials
Description: Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling & self-help materials
Description: Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone counseling & self-help materials
Description: Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation.
Study: NCT03710733

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sequential boost
Description: Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concomitant boost
Description: Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
Study: NCT04555369

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ct-DNA
Description: The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
Study: NCT00008333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT01755156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to omarigliptin
Description: Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to glimepiride
Description: Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
Study: NCT03142451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 minocycline foam 1.5%
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study: NCT01404260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine +Carboplatin
Description: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine +Carboplatin
Description: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
Study: NCT00901563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigaptide
Description: Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
Study: NCT02074137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL XRP6258
Description: Pharmaceutical form:Solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT02376335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
Study: NCT02832947

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 10 mg
Description: At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
Study: NCT01749566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment D
Description: The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment D
Description: The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment D
Description: The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment D
Description: The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
Study: NCT04404439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline + topiramate
Description: Treatment group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil + paroxetine
Description: Treatment group 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03307096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microperc surgery
Description: Parents are treated by Microperc Percutaneous Nephrolithotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FURS
Description: Parents are treated by FURS
Study: NCT03225222

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: prostate biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: prostate biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: prostate biopsy
Study: NCT01795131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Study: NCT04170634

Intervention type: OTHER
Intervention: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation
Description: Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
Study: NCT01186497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
Study: NCT02785289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal cell collection will be performed with the two types of indicated swab.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal cell collection will be performed with the two types of indicated swab.
Study: NCT03800303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Description: 2-week family-based treatment
Study: NCT00437970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15mg of Pioglitazone taken orally twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg of Metformin taken orally twice a day
Study: NCT01795131

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01990352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
Study: NCT00949078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
Study: NCT02916238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.